Arfian Muzaki1, Gurmeet Singh2
1Program Studi Profesi Dokter, Fakultas Kedokteran Universitas Indonesia
2Divisi Respirologi dan Penyakit Kritis, Dept. Ilmu Penyakit Dalam,RSUPN Cipto Mangunkusumo,
Fakultas Kedokteran Universitas Indonesia
Background: Corona virus disease 2019 (COVID-19) is a new disease caused by the SARS-CoV2 virus and announced to be a global pandemic. Symptoms can vary in different people and are divided into asymptomatic, mild, moderate, and severe. Vitamin D is said to have an effect on lowering the risk of microbial infection and death. Therefore, vitamin D is given to COVID-19 patients with the hope of reducing clinical deterioration and mortality.
Objective: To assess the effect of vitamin D on clinical deterioration and mortality in COVID-19 patients based on studies that have been conducted.
Methods: Searching randomized controlled trials and cohorts in three databases, namely PubMed, Scopus, and Cochrane. Articles will be selected and then subjected to a critical review using guidelines from the University of Oxford’s Center for Evidence-based Medicine (CEBM).
Results: A total of three studies were selected with one randomized controlled trial and two cohort studies. All studies claim that offering vitamin D therapy decreased the incidence of admission of patients to the ICU (invasive mechanical ventilation) and mortality. Study drawbacks may bias and influence the significance of the association between vitamin D administration and clinical deterioration.
Conclusion: Administration of vitamin D in hospitalized COVID-19 patients to reduce clinical worsening of patients.
Keywords: Adult, COVID-19, Vitamin D, cholecalciferol, calcifediol